Tag: anaplastic lymphoma kinase (ALK)

April 11, 2017 Off

Roche’s Alecensa beats crizotinib in certain lung cancer

By Dino Mustafić

Roche’s randomised phase III ALEX study showed that Alecensa (alectinib) as an initial (first-line) treatment significantly reduced the risk of disease worsening or death (progression-free survival, PFS) compared to crizotinib in people with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).